| Literature DB >> 27310255 |
Li-Fen Hu1,2, Guo-Sheng Chen1, Qin-Xiang Kong1, Li-Ping Gao1, Xi Chen1, Ying Ye1,2, Jia-Bin Li1,2,3.
Abstract
AIMS: This study was carried to reveal the genetic mechanisms of trimethoprim/sulfamethoxazole (SXT) resistance.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27310255 PMCID: PMC4911037 DOI: 10.1371/journal.pone.0157693
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Oligonucleotide primers used in this study.
| primers | Sequences(5'-3') | Target | Reference |
|---|---|---|---|
| class1 integrase | |||
| class 1 integron | |||
| class 2 integron | |||
| class 3 integranse | |||
| This study | |||
| 3’flanking nucleotide of | This study | ||
| 5’flanking nucleotide of | This study | ||
| 16s RNA-R | 16s RNA | This study | |
| 16s RNA-F |
SP, special primer; F, forward; R, reverse.
Fig 1Schematic diagram of resistance gene cassettes located in the class 1 integron from Stenotrophomonas maltophilia isolates.
Distribution of resistance determinants to trimethoprim/sulfamethoxazole resistance in clinical Stenotrophomonas maltophilia isolates.
| year (n) | genes | SXT | MIC(mg/L) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S(%) | R(%) | range | MIC50 | MIC90 | |||||||||
| 2005(26) | 11(42.3) | 2(7.7) | 1(3.8) | 11(42.3) | 21(80.8) | 5(19.2) | 0.25/4.75-32/608 | 0.25/4.75 | 8/152 | ||||
| 2006(26) | 12(46.2) | 2(7.7) | 1(3.8) | 2(7.7) | 13(50) | 18(69.2) | 8(30.8) | 0.25/4.75-32/608 | 0.25/4.75 | 16/304 | |||
| 2007(26) | 18(69.2) | 3(11.5) | 1(3.8) | 2(7.7) | 2(7.7) | 17(65.4) | 17(65.4) | 9(34.6) | 0.25/4.75-32/608 | 0.25/4.75 | 16/304 | ||
| 2008(24) | 13(54.2) | 6(25) | 3(12.5) | 3(12.5) | 15(62.5) | 16(66.7) | 8(33.3) | 0.25/4.75-32/608 | 0.25/4.75 | 32/608 | |||
| 2009(43) | 23(53.5) | 5(11.6) | 5(11.6) | 26(60.5) | 30(69.8) | 13(30.2) | 0.25/4.75-32/608 | 0.5/9.5 | 32/608 | ||||
| 2010(43) | 23(53.5) | 15(34.9) | 2(4.7) | 3(7.0) | 2(4.7) | 35(81.4) | 24(55.8) | 19(44.2) | 0.25/4.75-32/608 | 0.5/9.5 | 32/608 | ||
| 2011(20) | 12(60) | 10(50) | 1(5) | 1(5) | 4(20) | 2(10) | 3(15) | 17(85) | 12(60) | 8(40) | 0.25/4.75-32/608 | 1/19 | 32/608 |
| 2012(32) | 17(53.1) | 16(50) | 1(3.1) | 1(3.1) | 4(12.5) | 5(15.6) | 4(12.5) | 30(93.8) | 15(46.9) | 17(53.1) | 0.25/4.75-32/608 | 4/76 | 32/608 |
| 2013(28) | 25(89.3) | 13(46.4) | 1(3.6) | 6(21.4) | 5(17.9) | 1(3.6) | 24(85.7) | 14(50) | 14(50) | 0.25/4.75-32/608 | 4/76 | 32/608 | |
| 2014(32) | 25(78.1) | 7(21.9) | 5(15.6) | 3(9.4) | 30(93.7) | 17(53.1) | 15(46.9) | 0.25/4.75-32/608 | 4/76 | 32/608 | |||
| Total (300) | 179(59.7) | 77(25.7) | 4(1.3) | 4(1.3) | 35(11.7) | 25(8.3) | 8(2.7) | 218(72.7) | 184(61.4) | 116(38.7) | 0.25/4.75-32/608 | 0.5/9.5 | 32/608 |
SXT, trimethoprim-sulfamethoxazole; S, susceptible; R, resistant; MIC, Minimal inhibitory concentration; MIC50, the concentration needed to inhibit 50% of the strains; MIC90, the concentration needed to inhibit 90% of the strains
Resistance determinants contributing to trimethoprim/sulfamethoxazole resistance in clinical Stenotrophomonas maltophilia isolates.
| Genes | SXT-resistant isolates (%) | SXT-susceptible isolates (%) | Multivariate Analysis | ||
|---|---|---|---|---|---|
| n = 116 | n = 184 | OR | 95%CI | ||
| 94(81.0) | 85(46.2) | 22 | (2.08–4.24) | 0.000 | |
| 59(50.9) | 18(9.8) | 49 | (2.87–5.12) | 0.000 | |
| 2(1.7) | 2(1.1) | 1 | (-2.05–2.53) | 0.830 | |
| 3(2.6) | 1(0.5) | 11 | (-1.17–6.09) | 0.180 | |
| 29(25) | 6(3.3) | 20 | (1.84–4.20) | 0.000 | |
| 18(15.5) | 7(3.8) | 10 | (1.10–3.53) | 0.000 | |
| 5(4.3) | 3(1.6) | 11 | (0.49–4.33) | 0.010 | |
| 97(83.6) | 121(65.8) | 4 | (0.70–2.46) | 0.000 | |
SXT, trimethoprim-sulfamethoxazole.